PMID- 33235818
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20231112
IS  - 2162-4011 (Print)
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Nov 11
TI  - Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail 
      vaccination clinical studies in patients with refractory/persistent disease of 
      uterine cervical cancer and ovarian cancer [phase 2].
PG  - 1838189
LID - 10.1080/2162402X.2020.1838189 [doi]
LID - 1838189
AB  - We had conducted phase 1/2 studies of cancer vaccination therapy using neo-tumor 
      antigens in patients with refractory/persistent cervical cancer (CC) and ovarian 
      cancer (OC) to assess the feasibility and efficacy. Enrollees must be 
      refractory/persistent disease for usual treatments with Human Leukocyte 
      Antigen-A*0201 or A*2402. The targets were epitope peptides obtained from driver 
      genes in surviving pathways as follows: for CC A*0201, peptides from Up 
      Regulating Lung Cancer 10 gene (URLC10) and Hypoxia-inducible gene 2 (HIG-2) and 
      for OC A*0201, HIG2, VEGFR (vascular epithelial growth factor receptor) 1 and 2 
      were used. For CC A*2402, Forkhead Box M1 (FOXM1), Maternal Embryonic Leucine 
      zipper Kinase (MELK), and Holliday Junction Recognition Protein (HJURP) were 
      used. For OC A*2402, cocktails of peptides from FOXM1, MELK, HJURP, VEGFR1, and 
      VEGFR2 were used. Subcutaneous administration was performed with adjuvant weekly. 
      The toxicity profiles and tumor-response were analyzed in eight-week interval. 
      Sixty-six patients were accrued, and 64 were evaluable for adverse events (AEs), 
      and 35 for response. AEs of G2/3 dermatologic reaction (DR) of injection site had 
      been identified in 15.6% and no other severe AEs were detected. Response rate in 
      OC and CC were 22.9% and 20%, respectively. Median overall survival showed longer 
      in performance status (PS) 0 (versus PS1/2), in CRP negative (versus positive) 
      and in DR positive (versus negative) such as 8.7 m versus 1.2 m (p < .001), 8.8 m 
      versus 3.0 m (p < .05) and 10.2 m versus 1.2 m (p < .001), respectively. In 
      conclusion, our vaccination therapy was feasible and effective in this cohort of 
      patients.
CI  - (c) 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
FAU - Takeuchi, Satoshi
AU  - Takeuchi S
AUID- ORCID: 0000-0001-8868-6462
AD  - Department of Obstetrics and Gynecology, Iwate Medical University School of 
      Medicine, Yahaba town, Japan.
AD  - Division of Gynecologic Oncology, Department of Gynecology, Women Health Care, 
      Kobe Tokushukai Hospital Women's Cancer Center, Gynecologic Oncology, Kobe, 
      Japan.
FAU - Kagabu, Masahiro
AU  - Kagabu M
AD  - Department of Obstetrics and Gynecology, Iwate Medical University School of 
      Medicine, Yahaba town, Japan.
FAU - Shoji, Tadahiro
AU  - Shoji T
AD  - Department of Obstetrics and Gynecology, Iwate Medical University School of 
      Medicine, Yahaba town, Japan.
FAU - Nitta, Yukari
AU  - Nitta Y
AD  - Department of Obstetrics and Gynecology, Iwate Medical University School of 
      Medicine, Yahaba town, Japan.
FAU - Sugiyama, Toru
AU  - Sugiyama T
AD  - Department of Obstetrics and Gynecology, Iwate Medical University School of 
      Medicine, Yahaba town, Japan.
AD  - Gynecology, St. Mary's Hospital, Kurume, Japan.
FAU - Sato, Junya
AU  - Sato J
AD  - Department of Obstetrics and Gynecology, Iwate Medical University School of 
      Medicine, Yahaba town, Japan.
AD  - Department of Pharmacy, Shizuoka Cancer Center, Tokyo, Japan.
FAU - Nakamura, Yusuke
AU  - Nakamura Y
AD  - Department of Cancer, The Institute of Medical Science, The University of Tokyo, 
      Tokyo, Japan.
AD  - Department of Cancer precision Medicine, Cancer Institute Hospital of JFCR 
      (Japanese Foundation for Cancer Research), Tokyo, Japan.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201111
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
RN  - 0 (Epitopes)
RN  - 0 (Peptides)
RN  - EC 2.7.1.- (MELK protein, human)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
MH  - Epitopes
MH  - Female
MH  - Humans
MH  - Immunotherapy/adverse effects
MH  - *Ovarian Neoplasms/therapy
MH  - Peptides
MH  - Protein Serine-Threonine Kinases
MH  - *Uterine Cervical Neoplasms/therapy
MH  - Vaccination
PMC - PMC7671072
OTO - NOTNLM
OT  - HLA-A restricted peptides
OT  - cervical cancer
OT  - ovarian cancer
OT  - peptides vaccination immunotherapy
OT  - persistent
OT  - refractory
EDAT- 2020/11/26 06:00
MHDA- 2020/11/26 06:01
PMCR- 2020/11/11
CRDT- 2020/11/25 05:47
PHST- 2020/11/25 05:47 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/11/26 06:01 [medline]
PHST- 2020/11/11 00:00 [pmc-release]
AID - 1838189 [pii]
AID - 10.1080/2162402X.2020.1838189 [doi]
PST - epublish
SO  - Oncoimmunology. 2020 Nov 11;9(1):1838189. doi: 10.1080/2162402X.2020.1838189.